RecruitingNCT07160153

Cannabis Abstinence and Neurocognitive Assessment in Adolescence


Sponsor

University Hospital Pilsen

Enrollment

29 participants

Start Date

Dec 3, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Cannabis Abstinence and Neurocognitive Assessment in Adolescence


Eligibility

Min Age: 15 YearsMax Age: 18 Years

Inclusion Criteria1

  • Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Exclusion Criteria3

  • psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
  • somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
  • Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTNeurocognitive assessment

Neurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs Other psychometrics: The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)

DIAGNOSTIC_TESTUrine toxicological assessment

Urine toxicological assessment


Locations(1)

University Hospital Pilsen

Pilsen, Czechia, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07160153


Related Trials